Herbert Smith Freehills Kramer (HSF Kramer) is proud to have advised PYC Therapeutics Limited (ASX:PYC) (PYC) on its current capital raising to raise up to approximately A$653 million, comprising a placement of A$128 million to leading US specialist life sciences investors and an accelerated non-renounceable entitlement offer of up to A$525 million.
Upon successful completion of the capital raising, PYC will be funded into CY2030 with clinical trial progress and important near-term human efficacy data expected in all four of its drug development programs.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
